Is Geron Corporation (GERN) a Buy, Sell, or Hold?
NASDAQ : GERN
Geron Corporation
$1.42 USD
-$0.03 (-2.07%)
- Volume
- 3.29M
- Average Volume
- 12.69M
- Market Capitalization
- $910.96M
- P/E Ratio
- -13.61
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.01
- Year Low
- $1.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.78
Company Overview
NASDAQ
Harout Semerjian
Biotechnology
Healthcare
GERN
258
US
USD
Liquidity Metrics
1.10
6.78
6.78
0.96
0.00
Sales & Valuation
$183.88M
4.65
4.15
-7.21
-0.19
Profitability
-$0.13
-$85.78M
-35.48%
-35.48%
-28.90%
-13.03%
P/E Metrics
-13.61
-0.20
-0.20
Analyst Price Target & Rating
$6.00
$8.00
$4.00
1/5
22 Analysts
-76.33%
Financial Health Scores
-1.99
1/9
$424.96M
$534.12M
$305.01M
-$37.98M
Key Metrics (TTM)
$1.09B
5.57
-29.56
6.78
-28.90%
-7.77%
-7.32%
-13.86%
-94 days
Company Executives
| Name | Title |
|---|---|
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer |
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer |
| Harout Semerjian | Chief Executive Officer, President & Director |
| Shannon Odam | Executive Vice President & Chief People Officer |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Geron Corporation (NASDAQ:GERN) Stock
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California. ...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-22 16:01:00
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 07:00:00
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
2026-07-15 09:00:00
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 16:26:00
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
2026-07-13 08:00:00
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
2026-07-01 10:11:08
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M expected. Management is now prioritizing high-volume community accounts, aiming to shift sales mix from academic centers to the broader 80% community-driven market.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-18 16:01:00
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
2026-06-08 11:38:32
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Geron Corporation (GERN) stock price?
-
Geron Corporation(NASDAQ:GERN) stock price is $1.42 in the last trading session. During the trading session, GERN stock reached the peak price of $2.01 while $1.04 was the lowest point it dropped to. The percentage change in GERN stock occurred in the recent session was --2.07% while the dollar amount for the price change in GERN stock was -$0.03.
-
GERN's industry and sector of operation?
-
The NASDAQ listed GERN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GERN?
-
Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer
Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary
Aron Feingold | Vice President of Investor Relations & Corporate Communications
Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer
Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer -
How many employees does GERN have?
-
Number of GERN employees currently stands at 258. GERN operates from 919 East Hillsdale Boulevard, Foster City, CA 94404, US.
-
Link for GERN official website?
-
Official Website of GERN is: https://www.geron.com
-
How do I contact GERN?
-
GERN could be contacted at phone #650 473 7700 and can also be accessed through its website. GERN operates from 919 East Hillsdale Boulevard, Foster City, CA 94404, US.
-
How many shares of GERN are traded daily?
-
The average number of GERN shares traded daily for last 3 months was 12.69M.
-
What is the market cap of GERN currently?
-
The market value of GERN currently stands at $910.96M with its latest stock price at $1.42